Residency · Residency · Psychiatry
Catatonia: Recognition and Emergency Treatment
Definition and Epidemiology
What Is Catatonia?
A neuropsychiatric syndrome characterized by motor, behavioral, and autonomic abnormalities. NOT a diagnosis in itself -- it is a specifier or condition associated with an underlying etiology. DSM-5-TR classifies it as: Catatonia associated with another mental disorder (e.g., schizophrenia, bipolar disorder, MDD) Catatonic disorder due to another medical condition. Unspecified catatonia. Prevalence: 5-20% of acute psychiatric inpatients; often unrecognized. Occurs in mood disorders more commonly than in schizophrenia (contrary to historical association) ~20-30% of bipolar mania, ~10-15% of severe depression, ~10% of schizophrenia.
Clinical Presentation
DSM-5-TR Criteria
Three or more of the following 12 features: Stupor: no psychomotor activity; not actively relating to environment. Catalepsy: passive induction of posture held against gravity. Waxy flexibility: slight, even resistance to positioning by examiner. Mutism: no or very little verbal response. Negativism: opposition or no response to instructions or external stimuli. Posturing: spontaneous and active maintenance of a posture against gravity. Mannerism: odd, circumstantial caricature of normal actions. Stereotypy: repetitive, abnormally frequent, non-goal-directed movements. Agitation: not influenced by external stimuli. Grimacing. Echolalia: mimicking another's speech. Echopraxia: mimicking another's movements.
Retarded vs. Excited Catatonia
| Feature | Retarded (Akinetic) Catatonia | Excited Catatonia | Malignant Catatonia |
|---|---|---|---|
| Motor presentation | Stupor, immobility | Agitation, combativeness | Rigidity + either |
| Key signs | Catalepsy, waxy flexibility, posturing, mutism | Stereotypies, echolalia/echopraxia, impulsivity | Hyperthermia, autonomic instability |
| Common misdiagnosis | Psychotic withdrawal, depression | Psychotic agitation, mania | NMS, sepsis |
| Labs | Usually normal | Usually normal | Elevated CK, WBC, LFTs |
| Mortality | Low (unless malnutrition/DVT) | Moderate (exhaustion) | 10-20% even with treatment |
| Setting | Can manage on psychiatric unit | May need seclusion precautions | ICU required |
Retarded (akinetic) catatonia: the classic presentation; stupor, mutism, catalepsy, waxy flexibility, posturing, negativism. Excited catatonia: agitation, stereotypies, echolalia/echopraxia, impulsivity, combativeness; often misidentified as psychotic agitation. Patients can fluctuate between retarded and excited presentations.
Malignant Catatonia
A life-threatening emergency characterized by: Fever (hyperthermia) Autonomic instability (tachycardia, labile blood pressure, diaphoresis) Rigidity. Altered consciousness. Elevated CK (rhabdomyolysis) Mortality rate: 10-20% even with treatment. Requires ICU-level care. Overlaps significantly with neuroleptic malignant syndrome (NMS)
Bush-Francis Catatonia Rating Scale (BFCRS)
Structure and Use
The most widely used standardized tool for assessing catatonia. Screening instrument: 14 items; presence of >=2 items is a positive screen. Full rating scale: 23 items scored 0-3 for severity; used to track treatment response. Items include: excitement, immobility/stupor, mutism, staring, posturing/catalepsy, grimacing, echopraxia/echolalia, stereotypy, mannerisms, verbigeration, rigidity, negativism, waxy flexibility, withdrawal. Should be administered at bedside as part of the physical examination -- it requires direct observation and interaction with the patient.
Differential Diagnosis and Etiologic Workup
Medical Etiologies
Neurological: encephalitis (especially anti-NMDA receptor encephalitis), seizures (nonconvulsive status epilepticus), stroke, traumatic brain injury, neurodegenerative disease. Metabolic/endocrine: hepatic encephalopathy, uremia, hyponatremia, hypercalcemia, thyroid storm, adrenal crisis. Autoimmune: anti-NMDA receptor encephalitis (should be considered in all cases of new-onset catatonia, especially in young women), SLE cerebritis. Infectious: viral encephalitis, HIV, neurosyphilis. Toxic: neuroleptic malignant syndrome, serotonin syndrome, phencyclidine, other drug effects.
Psychiatric Etiologies
Mood disorders (most common psychiatric cause) Schizophrenia and schizoaffective disorder. Autism spectrum disorder (high prevalence of catatonic features) Acute stress/trauma.
Workup
CBC, CMP, TSH, CK, urinalysis, urine drug screen. Brain MRI. EEG (to exclude nonconvulsive status epilepticus) Lumbar puncture with CSF analysis (if encephalitis suspected -- anti-NMDA receptor antibodies) Consider: autoimmune panel, HIV, RPR, paraneoplastic antibodies.
Treatment
The Lorazepam Challenge Test
Both diagnostic and therapeutic. Administer lorazepam 1-2 mg IV (or IM if IV access not available) Assess at 1-2 hours for improvement in catatonic signs using BFCRS. Positive response: >=50% improvement in BFCRS score strongly supports diagnosis. Sensitivity: ~60-80% for catatonia (not all catatonia responds to benzodiazepines) If positive: continue lorazepam; titrate up as needed.
Benzodiazepine Treatment
Lorazepam is the first-line pharmacotherapy for catatonia. Starting dose: 1-2 mg IV/IM/PO every 6-8 hours. Titrate rapidly based on response; doses of 16-24 mg/day (or higher) may be needed. Response typically occurs within hours to days. Continue for weeks to months with gradual taper to prevent relapse. IV lorazepam preferred for acute/severe cases for reliable absorption and faster onset. If no response to adequate lorazepam dose after 3-5 days, proceed to ECT.
Electroconvulsive Therapy
ECT is the definitive treatment for catatonia, especially: Lorazepam-resistant catatonia. Malignant catatonia (emergency indication) Catatonia in patients who cannot tolerate high-dose benzodiazepines. Response rates: 80-100% for catatonia (among the highest for any psychiatric indication) Bilateral electrode placement typically used. Daily treatments may be needed initially for malignant catatonia. Typical course: 6-12 treatments.
NMS/Catatonia Overlap
NMS and malignant catatonia share features: rigidity, hyperthermia, autonomic instability, altered consciousness, elevated CK. Critical clinical point: antipsychotics can cause NMS, and they can worsen catatonia. If a patient on antipsychotics develops catatonia/NMS: STOP the antipsychotic immediately. Treat with lorazepam +/- dantrolene (for NMS) +/- ECT. Do NOT administer antipsychotics to treat catatonia (common and dangerous error)
<image> A clinical recognition diagram for catatonia showing the key physical examination findings. Illustrate a patient figure with labeled examination maneuvers: testing for catalepsy (positioning the arm and observing if maintained), waxy flexibility (feeling for resistance during passive movement), mitgehen (arm rises with light touch), gegenhalten (variable resistance to passive movement), ambitendency (patient appears stuck between opposing movements), and the grasp reflex. Include a checklist of the 12 DSM-5-TR catatonic features with bedside testing methods for each. Medical examination illustration style. </image>
<image> A treatment algorithm for catatonia. Start with "Clinical suspicion of catatonia (>=2 BFCRS features)." Step 1: Etiologic workup (medical vs. psychiatric cause). Step 2: Lorazepam challenge (1-2 mg IV). Branch on response: positive (continue lorazepam, titrate) vs. negative/partial (increase dose up to 16-24 mg/day for 3-5 days). If still inadequate: ECT. Parallel track for malignant catatonia: ICU admission, IV lorazepam + supportive care, urgent ECT. Include a prominent warning box: "STOP antipsychotics if catatonia is suspected." Color-coded by urgency. </image>
<image> A Venn diagram showing the clinical overlap between malignant catatonia, neuroleptic malignant syndrome (NMS), and serotonin syndrome. In each circle, list the distinguishing features. In the overlapping regions, show shared features (rigidity, hyperthermia, autonomic instability). Include a comparison table below with columns for each syndrome showing: typical causative agents, key distinguishing clinical features, laboratory findings, and treatment approach. Medical differential diagnosis format. </image>
Clinical Pearls
Catatonia is far more common than most clinicians realize -- screen for it routinely in patients presenting with stupor, mutism, or unexplained psychomotor changes. Catatonia occurs more commonly in mood disorders than in schizophrenia -- do not limit your differential to psychotic disorders. The lorazepam challenge is both a diagnostic test and a treatment -- a positive response strongly supports the diagnosis and guides ongoing management. NEVER give antipsychotics to a catatonic patient -- antipsychotics can worsen catatonia and precipitate NMS; this is one of the most important lessons in psychiatric emergency management. Anti-NMDA receptor encephalitis should be on the differential for every case of new-onset catatonia, especially in young women -- CSF antibody testing may be needed. Malignant catatonia is a medical emergency with significant mortality -- treat aggressively with IV lorazepam and emergent ECT; do not wait. Patients with autism spectrum disorder are at increased risk for catatonia, which may present atypically -- maintain a high index of suspicion.
References
- Bush G, Fink M, Petrides G, et al. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand. 1996;93(2):129-136.
- Sienaert P, Dhossche DM, Vancampfort D, et al. A clinical review of the treatment of catatonia. Front Psychiatry. 2014;5:181.
- Fink M, Taylor MA. Catatonia: A Clinician's Guide to Diagnosis and Treatment. Cambridge University Press; 2003.
- Oldham MA, Lee HB. Catatonia vis-a-vis delirium: the significance of recognizing catatonia in altered mental status. Gen Hosp Psychiatry. 2015;37(6):554-559.
- Dalmau J, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091-1098.
